Skip to main content
Premium Trial:

Request an Annual Quote

MilliporeSigma Licenses CRISPR-Cas9 Technology to Cellecta

NEW YORK – MilliporeSigma, the US and Canadian life science business of German biotechnology firm Merck KGaA, said on Wednesday that it has signed an agreement to license its patented CRISPR-Cas9 technology to functional genomics products and services provider Cellecta.

Financial and other terms of the deal were not disclosed.

Cellecta provides its customers with RNAi and CRISPR technologies for the discovery and characterization of novel therapeutic targets and genetic profiling for drug and biomarker discovery and validation. The company said it will use the CRISPR IP it has licensed from MilliporeSigma to offer CRISPR-mediated targeted gene knock-in services to give scientists more options for therapeutic and disease research.

"The technology enables us to provide a more comprehensive range of options for cell modification to our customers," Paul Diehl, Cellecta's chief operating officer, said in a statement. "More specifically, access to this technology allows us to conduct integrated knock-in which is a key component of our customers' drug testing."

MilliporeSigma said it currently holds 40 CRISPR-related patents worldwide in methods and composition, including the CRISPR-Cas9 foundational technology for genetic integration in mammalian cells. The company is actively licensing its CRISPR technology for therapeutic and other uses, and is seeking collaboration partners for research and product development.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.